Drug-maker Glenmark said that the American Arbitration Panel has granted its request for an interim order that prohibits Napo from terminating a collaboration agreement between the companies on Napo's anti-diarrheal compound Crofelemer.
The order does not allow Napo to treat the Agreement as terminated unless and until the panel issues its order, Glenmark told the Bombay Stock Exchange. The arbitration hearing is scheduled for late March, it added.
A month ago, Glenmark had said that it had approached the American Arbitration Association against Napo Pharmaceuticals, after the latter terminated the deal on its proprietary compound.
Napo had then said that it terminated a July 2005 collaboration agreement with Glenmark, as it was “disappointed that Glenmark did not move forward to make this first-in-class drug available in any one of the 140 countries in which it was licensed to do so.”
In its claim, Glenmark said that it sought, among other things, a declaration with respect to its exclusive rights to develop, commercialise and distribute the anti-diarrheal drug Crofelemer in 140 countries.
On Napo's purported termination of the Agreement, Glenmark said that it had formally requested the Arbitration Panel to issue an interim order directing Napo to comply with the Collaboration Agreement during the pendency of the arbitration.
Glenmark shares closed up about 3 percent on the BSE, at Rs 312 on Friday.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.